2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
Key Takeaways
- High-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) lowers LDL-C by 50% or more and is started or continued before discharge in every ACS patient regardless of the admission LDL-C.
- In very-high-risk ASCVD an LDL-C of 70 mg/dL or higher on maximally tolerated statin triggers a non-statin add-on: ezetimibe adds 13-20%, PCSK9 monoclonals and inclisiran add about 50-60%, bempedoic acid 17-25%.
- Most statin-associated muscle symptoms occur with a normal creatine kinase; myopathy is CK above 10 times the upper limit of normal and rhabdomyolysis above about 40 times normal with myoglobinuria.
- Simvastatin is capped at 20 mg daily with amiodarone, amlodipine or ranolazine and 10 mg daily with verapamil or diltiazem, and gemfibrozil should not be combined with any statin.
- Statin discontinuation after ACS is associated with increased mortality, so teach patients to call about muscle symptoms rather than self-discontinue, and place the cardiac rehabilitation referral before discharge.
Why Hyperlipidemia Sits on a Critical-Care Blueprint
The CMC test plan lists hyperlipidemia as sub-topic I.B.4 under Vascular Conditions, and chronic coronary disease underlies nearly every acute presentation on the unit. The exam is not asking you to run a lipid clinic. It is asking whether the cardiac nurse can identify the patient whose therapy is inadequate, recognize the adverse effects and drug interactions that surface in an intensive care environment, and deliver the discharge teaching that determines whether the plaque you just stented stays quiet.
Plaque Progression and the Concept of Stability
Atherosclerosis begins with endothelial injury and subendothelial retention of apolipoprotein B-containing lipoproteins: low-density lipoprotein (LDL), remnant particles, and lipoprotein(a). Oxidized LDL is engulfed by macrophages, which become foam cells and form the fatty streak. Smooth muscle cells migrate outward and lay down a collagen fibrous cap over an enlarging necrotic lipid core, producing the fibroatheroma. Vessels initially remodel outward (Glagov remodeling), so a plaque can be biologically advanced before angiography shows any narrowing.
What produces an acute event is not stenosis severity but cap integrity:
- Thin-cap fibroatheroma (TCFA) is a cap thinner than roughly 65 micrometers over a large lipid core with dense macrophage infiltration. Rupture of a TCFA causes about two-thirds of acute coronary syndromes, and most culprit lesions were less than 70% stenotic beforehand. This is why a reassuring stress test months earlier does not exclude ACS today, and it is a favorite exam trap.
- Plaque erosion is endothelial denudation over a proteoglycan-rich, less inflamed plaque. It accounts for roughly a quarter to a third of ACS and is relatively more common in younger patients, women, and smokers.
- Calcified nodule is a minority mechanism seen in elderly, heavily calcified and renal-failure vessels.
Lipid lowering works by changing this biology. Aggressive LDL reduction shrinks the lipid core, thickens the fibrous cap and reduces macrophage content, and at LDL-C values below roughly 70 mg/dL serial intravascular ultrasound studies demonstrate net plaque regression. That mechanism, plaque stabilization rather than cholesterol arithmetic, is also the version you teach the patient.
Chronic Coronary Disease and Angina Severity
Chronic coronary disease (CCD) is the term used by the 2023 AHA/ACC chronic coronary disease guideline in place of "stable ischemic heart disease." It covers patients after acute coronary syndrome or revascularization, patients with stable angina, ischemic cardiomyopathy, vasospastic or microvascular angina, and patients with coronary disease found on imaging. Grade the symptom burden with the Canadian Cardiovascular Society (CCS) class, because that is what drives escalation and what an exam stem uses as shorthand.
| CCS class | Description |
|---|---|
| I | Angina only with strenuous, rapid or prolonged exertion; ordinary activity is not limited |
| II | Slight limitation: angina walking more than two blocks on the level or climbing more than one flight of stairs at a normal pace |
| III | Marked limitation: angina walking one to two blocks on the level or climbing one flight of stairs at a normal pace |
| IV | Inability to perform any physical activity without discomfort; anginal symptoms may occur at rest |
The class alone is never the whole answer. A patient who moves from CCS II to CCS III or IV over a few weeks has a crescendo pattern, which is by definition unstable angina and belongs in an acute evaluation pathway rather than a routine outpatient titration.
The Lipid Panel and Current Targets
| Measure | How derived | Where it matters |
|---|---|---|
| LDL-C | Calculated (Friedewald) or measured directly | Primary treatment metric; 70 mg/dL is the threshold for adding non-statin therapy in very-high-risk ASCVD, and many clinicians drive toward below 55 mg/dL after recurrent events |
| Non-HDL-C | Total cholesterol minus HDL-C | More reliable than LDL-C when triglycerides are elevated; goal is generally 30 mg/dL above the LDL-C goal, so below 100 mg/dL when the LDL-C goal is below 70 |
| Triglycerides | Measured | 150-499 mg/dL is moderate hypertriglyceridemia; 500 mg/dL or higher is severe and carries pancreatitis risk |
| Lipoprotein(a) | Measured once in a lifetime | 50 mg/dL or about 125 nmol/L and above is a risk-enhancing factor; genetically determined and not meaningfully lowered by statins |
| Apolipoprotein B | Measured | Counts atherogenic particles; useful when LDL-C looks acceptable in diabetes or metabolic syndrome |
Very-high-risk ASCVD, the category that triggers the most aggressive therapy, means a history of multiple major ASCVD events (acute coronary syndrome, myocardial infarction, ischemic stroke, symptomatic peripheral arterial disease) or one major event plus multiple high-risk conditions such as age 65 or older, diabetes, hypertension, chronic kidney disease, current smoking, heart failure, prior bypass or PCI, or a persistent LDL-C of 100 mg/dL or higher despite maximal therapy. Screening lipid panels no longer require fasting unless triglycerides exceed roughly 400 mg/dL.
A patient taking rosuvastatin 20 mg daily and amiodarone 200 mg daily for atrial fibrillation is admitted with an NSTEMI. Admission LDL-C is 84 mg/dL and creatine kinase is normal. Which action is most appropriate?
Statin Therapy: Intensity, Not Brand
Statins are prescribed by intensity, defined by the expected percentage LDL-C reduction, not by milligram equivalence between drugs.
| Intensity | Expected LDL-C reduction | Agents and daily doses |
|---|---|---|
| High | 50% or more | Atorvastatin 40-80 mg; rosuvastatin 20-40 mg |
| Moderate | 30-49% | Atorvastatin 10-20 mg; rosuvastatin 5-10 mg; simvastatin 20-40 mg; pravastatin 40-80 mg; lovastatin 40 mg; fluvastatin XL 80 mg; pitavastatin 1-4 mg |
| Low | Less than 30% | Simvastatin 10 mg; pravastatin 10-20 mg; lovastatin 20 mg; fluvastatin 20-40 mg |
The 2025 AHA/ACC acute coronary syndrome guideline is unambiguous: start or continue a high-intensity statin in every ACS patient before discharge, regardless of the admission LDL-C. Do not wait for an outpatient panel and do not down-titrate because the LDL "looks good." Early high-intensity statin therapy is a plaque-stabilization and periprocedural-infarction intervention, and the discharge prescription is the single strongest predictor of whether the patient is still taking a statin a year later.
If the patient is already on maximally tolerated statin therapy and LDL-C remains 70 mg/dL or higher, adding a non-statin agent is a Class 1 recommendation. When LDL-C is 55-69 mg/dL after a recent event, further intensification is reasonable.
Statin-Associated Muscle Symptoms
| Presentation | Creatine kinase (CK) | What happens |
|---|---|---|
| Myalgia: aching, weakness or cramping, usually proximal and symmetric | Normal or below 3 times the upper limit of normal | Continue the statin; investigate other causes; consider dose reduction or a switch to a different agent |
| Myopathy/myositis | Above 10 times the upper limit of normal with symptoms | Hold the statin, hydrate, recheck CK and renal function |
| Rhabdomyolysis | Above 40 times the upper limit of normal, often above 10,000 U/L, with myoglobinuria, dark urine and rising creatinine | Stop the statin permanently, give aggressive intravenous fluids, monitor potassium and renal function closely |
| Statin-associated autoimmune myopathy | Markedly elevated and persists after discontinuation; anti-HMG-CoA reductase antibodies present | Rare; requires immunosuppression and permanent statin avoidance |
What the nurse actually does with a muscle complaint is investigate rather than discontinue. Take a real symptom history including onset relative to the start or dose change, symmetry, and proximal versus distal distribution. Draw a CK and a basic metabolic panel, and check thyroid function, because untreated hypothyroidism is a classic amplifier of statin muscle symptoms. Review the medication list for a newly added interacting drug, which in a cardiac unit is usually amiodarone, diltiazem, an azole antifungal, a macrolide, or colchicine. Blinded n-of-1 studies including SAMSON and StatinWISE showed that roughly 90% of the symptom burden patients attribute to statins also occurs during placebo periods, and most patients who are systematically rechallenged tolerate a statin, often a different one, at a lower dose, or on alternate days. Documenting "muscle pain" and letting the statin fall off the medication reconciliation by default is the failure mode this exam wants you to avoid.
Laboratory Monitoring
- Obtain a baseline ALT before initiating therapy. Routine periodic liver enzyme monitoring is not recommended; measure hepatic function if the patient develops symptoms suggesting hepatotoxicity such as unusual fatigue, anorexia, right upper quadrant pain, jaundice or dark urine.
- Baseline CK is not routinely required but is reasonable in higher-risk patients: prior statin intolerance, family history of myopathy, hypothyroidism, renal impairment, or several interacting drugs.
- Repeat the lipid panel 4-12 weeks after starting or changing therapy, then every 3-12 months. The repeat panel measures adherence as much as it measures pharmacology.
- Statins produce a small absolute increase in new-onset diabetes, roughly 0.1-0.2% per year with high-intensity therapy. This is not a reason to stop, because the cardiovascular benefit is an order of magnitude larger. Teach it proactively so the patient does not self-discontinue when another clinician mentions a rising hemoglobin A1c.
Four days after percutaneous coronary intervention, a patient started on atorvastatin 80 mg daily reports bilateral thigh and shoulder aching. Creatine kinase is 210 U/L with an upper limit of normal of 200 U/L, creatinine is unchanged, and the urine is clear. Which nursing action is the priority?
Non-Statin Agents
| Agent | Mechanism and adult dose | Additional LDL-C lowering | Nursing points |
|---|---|---|---|
| Ezetimibe | Blocks NPC1L1 intestinal sterol absorption; 10 mg orally daily | 13-20% | Generic, inexpensive, well tolerated; the usual first add-on. IMPROVE-IT showed event reduction when added to a statin after ACS |
| Evolocumab | PCSK9 monoclonal antibody; 140 mg subcutaneously every 2 weeks or 420 mg monthly | 50-60% | Refrigerated; let the autoinjector reach room temperature for 30-40 minutes before injecting. Injection-site reaction is the commonest adverse effect |
| Alirocumab | PCSK9 monoclonal antibody; 75-150 mg subcutaneously every 2 weeks | 50-60% | Same handling and teaching. Prior authorization is the practical barrier, so start the paperwork before discharge if the drug is going to happen at all |
| Inclisiran | Small interfering RNA that silences hepatic PCSK9 synthesis; 284 mg subcutaneously at baseline, at 3 months, then every 6 months | About 50% | Twice-yearly clinic-administered dosing removes the adherence problem entirely |
| Bempedoic acid | ATP-citrate lyase inhibitor; 180 mg orally daily | 17-25% | A prodrug activated in liver but not in skeletal muscle, so it is a genuine option in statin intolerance. Raises uric acid and can precipitate gout; small increase in tendon rupture. Reduced events in CLEAR Outcomes |
| Icosapent ethyl | Purified eicosapentaenoic acid; 2 g orally twice daily | Lowers triglycerides about 20%; not an LDL-lowering drug | REDUCE-IT showed a 25% relative reduction in major adverse cardiovascular events. Increases atrial fibrillation and bleeding, which matters in the anticoagulated cardiac patient |
| Fibrates (fenofibrate, gemfibrozil) | PPAR-alpha agonists | Triglyceride lowering | Reserved chiefly for triglycerides 500 mg/dL or higher to prevent pancreatitis; no proven event reduction when added to a statin |
| Niacin | Nicotinic acid | Raises HDL-C | No longer recommended. AIM-HIGH and HPS2-THRIVE showed no benefit added to a statin plus excess harm including hyperglycemia, infection and bleeding |
Fibrates and niacin lost first-line status because raising HDL-C and lowering triglycerides did not translate into fewer events on top of a statin. The exam-relevant summary: treat apolipoprotein B-containing particles and do not chase HDL-C.
Interactions That Matter in the Cardiac ICU
| Combination | Problem | Management |
|---|---|---|
| Simvastatin plus amiodarone | Amiodarone inhibits CYP3A4, markedly raising myopathy risk | Simvastatin maximum 20 mg daily; better still, use pravastatin, rosuvastatin or pitavastatin |
| Simvastatin plus verapamil or diltiazem | Same mechanism, stronger effect | Simvastatin maximum 10 mg daily |
| Simvastatin plus amlodipine or ranolazine | Moderate CYP3A4 inhibition | Simvastatin maximum 20 mg daily |
| Any statin plus gemfibrozil | Gemfibrozil inhibits statin glucuronidation; the highest rhabdomyolysis risk of any lipid combination | Avoid the combination; use fenofibrate if a fibrate is genuinely needed |
| Atorvastatin, simvastatin or lovastatin plus clarithromycin, erythromycin, azole antifungals, protease inhibitors or cyclosporine | Strong CYP3A4 inhibition | Hold the statin for the duration of the antimicrobial course or switch to a non-CYP3A4 statin |
| Atorvastatin plus digoxin | Digoxin concentration rises roughly 20% | Monitor the digoxin level and watch for toxicity |
| Any statin plus warfarin | INR may rise | Recheck INR after starting, stopping or changing the statin |
| Any statin plus colchicine | Additive myotoxicity | Monitor CK and symptoms; increasingly relevant now that colchicine is used in chronic coronary disease |
Pravastatin, rosuvastatin and pitavastatin are minimally metabolized by CYP3A4 and are the pragmatic choices for a patient on amiodarone or diltiazem. Simvastatin 80 mg is restricted to patients who have already tolerated that dose for at least 12 months without muscle toxicity.
Secondary Prevention and What You Actually Teach
The 2023 AHA/ACC chronic coronary disease guideline bundles the interventions below, and the bedside and discharge nurse owns most of them.
- High-intensity statin, with a non-statin added when the LDL-C goal is not met.
- Antiplatelet therapy: aspirin 81 mg daily indefinitely, plus the P2Y12 inhibitor for the duration specified after stenting.
- ACE inhibitor or angiotensin receptor blocker for hypertension, diabetes, chronic kidney disease, or an ejection fraction of 40% or less.
- Beta-blocker when there has been a recent myocardial infarction or the ejection fraction is 50% or less. Indefinite routine beta-blockade after myocardial infarction with a normal ejection fraction is no longer automatic.
- SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes with chronic coronary disease, for cardiovascular benefit independent of glucose control.
- Blood pressure below 130/80 mmHg, annual influenza vaccination, full smoking-cessation support including pharmacotherapy, and a Mediterranean-style dietary pattern.
- Cardiac rehabilitation referral before discharge, a Class 1 recommendation, typically 36 supervised sessions over about 12 weeks, associated with lower mortality and fewer readmissions. Only about a quarter to a third of eligible patients ever enroll, and the single strongest determinant is whether the referral was placed before the patient left the building. Place it, and tell the patient it was placed.
- Antianginal therapy for residual symptoms: a beta-blocker first, then a long-acting nitrate or a calcium channel blocker, with ranolazine 500-1,000 mg twice daily as an add-on that reduces ischemic burden without lowering heart rate or blood pressure. Vasospastic angina is treated with calcium channel blockers and nitrates, and non-selective beta-blockers are avoided because unopposed alpha stimulation worsens spasm.
The statin conversation is the highest-yield teaching you will do. Patients stop statins because they feel well, because a relative had muscle aches, or because a headline frightened them, and discontinuation after acute coronary syndrome is associated with higher mortality than never having started. Give the patient three sentences they can repeat: this medication stabilizes the plaque and is not treating a number on a lab report; do not stop it without calling us, even if your muscles ache, because there are other statins and other doses; and a new antibiotic, an antifungal, or grapefruit juice is a reason to call before the next dose.
A patient with chronic coronary disease on aspirin, metoprolol succinate and atorvastatin reports that he now develops chest pressure after walking one block on level ground, whereas three months ago he could walk a mile. How should the nurse characterize this and act?